Judge Opens Fairness Hearing On Bayer's $7.25 Billion Roundup Deal
The deal caps Monsanto's Non-Hodgkin Lymphoma payouts at $6,000 to $165,000-plus a claim, for anyone exposed in the US before February 17, 2026.
- Monsanto, owned by Bayer, agreed to pay up to $7.25 billion in King v. Monsanto Company.
- Payouts range $6,000 to $165,000 or more per Non-Hodgkin Lymphoma diagnosis, present or future.
- Class covers US exposure before February 17, 2026; opt-out and objection deadline passed June 4, 2026.
Why it matters: A price list for cancer claims ends the lawsuits; it never rules on whether Roundup causes the disease.
Weed Killer Class Settlement Notice (King v. Monsanto Company) - official court-authorized settlement site ↗ · Sep 14, 20269/14/26